Shanghai Junshi Biosciences (HKG:1877) said it expects 873 million yuan in 2025 losses, narrowing 32% year on year from a loss of 1.28 billion yuan, according to a Hong Kong bourse filing Friday.
Shares of the drug maker fell nearly 3% in late morning trade Monday.
The company's operating revenue is expected to increase by 28% year on year to 2.50 billion yuan, the firm said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments